EcoDrugPlus

Aurora Kinase A

Ensembl ID : ENSXETG00000012032
Gene Symbol: AURKA
17 Enzyme and pathways 5 View Cross-references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aurora Kinase B

Ensembl ID : ENSXETG00000009097
Gene Symbol: AURKB
26 Enzyme and pathways 5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Beta-Site App-Cleaving Enzyme 1

Ensembl ID : ENSXETG00000003749
Gene Symbol: BACE1
5 View Cross-references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bradykinin Receptor B2

Ensembl ID : ENSXETG00000013954
Gene Symbol: BDKRB2
5 View Cross-references
356 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Butyrylcholinesterase

Ensembl ID : ENSXETG00000006497
Gene Symbol: BCHE
10 Enzyme and pathways 5 View Cross-references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcitonin Receptor Like Receptor

Ensembl ID : ENSXETG00000013895
Gene Symbol: CALCRL
7 Enzyme and pathways 5 View Cross-references
147 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSXETG00000031848
Gene Symbol: CACNA1C
7 Enzyme and pathways 5 View Cross-references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSXETG00000007195
Gene Symbol: CACNA1F
5 View Cross-references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit

Ensembl ID : ENSXETG00000015130
Gene Symbol: CACNA1S
5 View Cross-references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit

Ensembl ID : ENSXETG00000005585
Gene Symbol: CACNA1A
6 Enzyme and pathways 5 View Cross-references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, R Type, Alpha 1e Subunit

Ensembl ID : ENSXETG00000012458
Gene Symbol: CACNA1E
6 Enzyme and pathways 5 View Cross-references
294 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Channel, Voltage-Dependent, T Type, Alpha 1g Subunit

Ensembl ID : ENSXETG00000006824
Gene Symbol: CACNA1G
2 Enzyme and pathways 5 View Cross-references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).